Abstract:ABSTRACT Viruses are used as expression vectors for protein synthesis, immunology research, vaccines, and therapeutics. Advantages of poxvirus vectors include the accommodation of large amounts of heterologous DNA, the presence of a cytoplasmic site of transcription, and high expression levels. On the other hand, competition of approximately 200 viral genes with the target gene for expression and immune recognition may be disadvantageous. We describe a vaccinia virus (VACV) vector that uses an early promoter to express the bacteriophage T7 RNA polymerase; has the A23R intermediate transcription factor gene deleted, thereby restricting virus replication to complementing cells; and has a heterologous gene regulated by a T7 promoter. In noncomplementing cells, viral early gene expression and DNA replication occurred normally but synthesis of intermediate and late proteins was prevented. Nevertheless, the progeny viral DNA provided templates for abundant expression of heterologous genes regulated by a T7 promoter. Selective expression of the Escherichia coli lac repressor gene from an intermediate promoter reduced transcription of the heterologous gene specifically in complementing cells, where large amounts might adversely impact VACV replication. Expression of heterologous proteins mediated by the A23R deletion vector equaled that of a replicating VACV, was higher than that of a nonreplicating modified vaccinia virus Ankara (MVA) vector used for candidate vaccines in vitro and in vivo , and was similarly immunogenic in mice. Unlike the MVA vector, the A23R deletion vector still expresses numerous early genes that can restrict immunogenicity as demonstrated here by the failure of the prototype vector to induce interferon alpha. By deleting immunomodulatory genes, we anticipate further improvements in the system. IMPORTANCE Vaccines provide an efficient and effective way of preventing infectious diseases. Nevertheless, new and better vaccines are needed. Vaccinia virus, which was used successfully as a live vaccine to eradicate smallpox, has been further attenuated and adapted as a recombinant vector for immunization against other pathogens. However, since the initial description of this vector system, only incremental improvements largely related to safety have been implemented. Here we described novel modifications of the platform that increased expression of the heterologous target gene and decreased expression of endogenous vaccinia virus genes while providing safety by preventing replication of the candidate vaccine except in complementing cells used for vector propagation.

[Screening and Application of Enhancer-Like Sequences from Vaccinia Virus].

Construction and Identification of a Vector Inserted with Gene of T7 RNA Polymerase

Detection of an Internal Translation Activity in the 5′ Region of Bombyx Mori Infectious Flacherie Virus

Construction of an eukaryotic expression vector containing IBDV VP2/4/3 and ChIL-2 fusion gene and their expression in Vero cells

Expression of Vp2e and Vp3 Genes from Marine Birnavirus (MABV) in Insect Cells

Construction and Expression of the Eukaryotic Expression Vector Pci-Chil-2-egfp and Enhancement of AIV Vaccine

[Expression of the Infectious Bursal Disease Virus Polyprotein in Vero Cells Using Attenuated Salmonella Typhimurium As Transgenic Carrier].

Expression of H5N1 influenza virus hemagglutinin protein fused with protein transduction domain in an alphavirus replicon system.

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins

Preliminary Study of the Effect of Human Alpha-fetoprotein Enhancer and Chicken HS-4 Insulator on the Gene Expression Mediated by Baculovirus Vectors

Cloning, Construction of Prokaryotic Expression System and Identification of Vibrio Vulni Ficus Vvha Gene

[Expression of IL-6 in Recombinant Non-Replicating Vaccinia Virus and Studying Its Effects on Immunogenicity].

Novel Enhanced Mammalian Cell Transient Expression Vector via Promoter Combination

The Construction of Attenuated Tiantan Recombinant Vaccinia Virus Vector with IFN-γ Receptor Gene Deletion

Identification of a Novel Insertion Site HVT-005/006 for the Generation of Recombinant Turkey Herpesvirus Vector

Enhanced transgene expression in mammalian cells by recombinant baculovirus vector containing bovine papillomavirus type 1 replication elements.

Development of a recombinant reporter Getah virus for antiviral drug screening assays

Enhanced Transgene Expression from Recombinant Single-Stranded D-sequence-substituted Adeno-Associated Virus Vectors in Human Cell Lines in Vitro and in Murine Hepatocytes in Vivo.

Studies on the gene elements of adenovirus and adeno associated virus to increase the expression efficiency of recombinant human il-6 in eukaryotic cells

Enhanced expression of GCRV VP6 in CIK cells by relative sequence optimization

An OriP/EBNA-1-based baculovirus vector with prolonged and enhanced transgene expression.